Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-10-08 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于终止与俄药集团相关合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the termination of cooperation with a Russian pharmaceutical group. It details the original cooperation agreements, the decision to terminate the cooperation due to geopolitical issues, and states that the termination will not impact the company's operations or performance. The document is short (780 characters) and serves as a formal announcement of a corporate event rather than a financial report or detailed management discussion. It does not contain financial data, audit information, or regulatory certifications. It is not related to board changes, voting results, or capital changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2023-10-08 Chinese
第四届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 24th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and future shareholder meeting plans. The content focuses on board decisions such as share repurchase plans, authorization for the board to handle repurchase matters, termination of cooperation agreements, and scheduling of a shareholder meeting. There is no financial data, earnings information, or audit content. The document is not a full report but a formal announcement of board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and contains detailed board meeting resolutions, not just a brief announcement or a certification, so it is not RPA or RNS. Confidence is high due to clear identification of board meeting content and voting results.
2023-10-08 Chinese
继续稳定股价措施实施结果公告
Director's Dealing Classification · 100% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the implementation results of measures to stabilize the stock price. It details the shareholding increase by certain directors and senior management, including the number of shares purchased, the purchase price range, and the total amount spent. The document references a previous announcement about the stock price stabilization plan and confirms compliance with relevant securities laws and regulations. The content focuses on share purchases by insiders to stabilize stock price rather than financial results, management changes, or other report types. The document length is 2641 characters, which is relatively short and is clearly an announcement of share transactions by company directors and senior management. Therefore, it fits the category of Director's Dealing (DIRS).
2023-10-08 Chinese
独立董事关于第四届董事会第二十四次会议审议事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent directors' opinion on board meeting resolutions related to a share repurchase plan. It discusses the board's approval and recommendation to submit the repurchase plan to the shareholders' meeting. The content focuses on governance and approval of capital actions rather than the actual execution or detailed financial data of the repurchase. The document length is short (861 characters) and it is an announcement of opinions and approvals rather than a full report or detailed financial disclosure. This fits best with a Transaction in Own Shares (POS) filing, which covers announcements related to share buybacks or repurchase plans.
2023-10-08 Chinese
关于召开2023年第十次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for the 2023 tenth extraordinary general meeting of shareholders of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items such as the proposal to continue implementing stock price stabilization measures and a share repurchase plan, authorization for the board to handle repurchase matters, registration methods, and contact details. It also contains an authorization proxy form for shareholders to delegate voting rights. The document is not a report of financial results or an audit, nor is it a transcript or presentation. It is a formal announcement and notice of a shareholders meeting with agenda and voting instructions, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the actual voting results or proxy solicitation materials, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains substantive meeting and voting information, not just a brief announcement. Therefore, the classification is PSI with high confidence.
2023-10-08 Chinese
股票解除限售公告
Regulatory Filings Classification · 95% confidence The document is titled '股票解除限售公告' which translates to 'Announcement of Stock Unlocking/Removal of Trading Restrictions'. It details the number of shares being unlocked from trading restrictions, the shareholders involved, reasons for unlocking, and the post-unlocking share capital structure. There is no financial data, earnings, or management discussion. The document is an official announcement regarding the lifting of trading restrictions on shares, which is a capital-related event but not a new share issue or capital change like a stock split or issuance. It is not a full financial report or earnings release. The document is short (1929 characters) and serves as a formal announcement of a capital-related event. This fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS).
2023-09-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.